Time to Monitor Serum Hydroxychloroquine Levels in Lupus?
BARCELONA, Spain — Monitoring serum hydroxychloroquine levels could help to ensure that patients with systemic lupus erythematosus (SLE) are being treated with the drug optimally, according to research reported at European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting.
Shivani Garg, MD, PhD
Shivani Garg, MD, PhD, an assistant professor of medicine and medical director of the Lupus and Lupus Nephritis Clinics at the School of Medicine and Public Health, University of Wisconsin-Madison, presented the findings of an observational study that confirmed and extended the results from an earlier study carried out by her research group that the ideal serum hydroxychloroquine level lay somewhere between a lower limit of 750 ng/mL and an upper limit of 1150 ng/mL for most patients with SLE.
The new study also showed that as estimated glomerular filtration rate (eGFR) increases, so does serum levels of hydroxychloroquine in the blood. This suggested that monitoring serum hydroxychloroquine levels may be particularly useful in people with chronic kidney disease.
Justification to Monitor
Alfred Kim, MD, PhD
Alfred Kim, MD, PhD, told Medscape Medical News that Garg's data gave justification to the idea that serum hydroxychloroquine levels need to be checked as a matter of routine.
'I think rheumatologists have been behind in checking drug blood levels in general. We don't check as routinely as compared to say nephrologists and gastroenterologists,' said Kim, who is an associate professor of medicine and associate professor of pathology and immunology at Washington University School of Medicine, St. Louis.
One of the known long-term risks associated with taking hydroxychloroquine is retinal toxicity, which is why regular eye examinations are undertaken. It takes time for the eye damage to accumulate, however, so 'how do you assume without knowing the levels that you're actually not introducing risk or not knowingly introducing risk downstream?'
Kim said there has been a tendency 'to follow clinical response and assume that if patients are not showing acute toxicity, that there will be no long-term toxicity.' This is 'obviously incorrect,' he said, and added that a 'culture change' is happening.
Optimum Dose Debated
'Hydroxychloroquine, or HCQ, is the cornerstone of lupus treatment as it prolongs both disease- and damage-free survival. However, the optimum dose of hydroxychloroquine is under great debate,' Garg said during her presentation.
Hydroxychloroquine is dosed according to body weight, with a recommended dose of 5 mg/kg. Prior data have shown that doses above this level double the risk for retinopathy compared with the level of 4-5 mg/kg/d, while those at 5 mg/kg/d or below are associated with a two- to six-fold increased risk for disease flares.
Measuring serum levels of hydroxychloroquine reflects metabolism, clearance, and adherence, Garg argued, and thus measuring and monitoring these levels could be a potential solution to ensuring the perfect balance between toxicity and efficacy.
Considering that 65% of hydroxychloroquine is cleared by the kidneys, one of the aims of the study was to identify if there are any thresholds of kidney function associated with supratherapeutic levels over time.
Study Design and Findings
Garg and colleagues combined prospectively collected data from two longitudinal cohorts from France and the US, encompassing a total of 1240 patients with SLE who had been treated with hydroxychloroquine.
The median age of the cohort was 40 years, and 92% were women. Just over half (58%) were being treated with doses of more than 5 mg/kg/d and 42% with doses of 5 mg/kg/d or lower. The cumulative hydroxychloroquine dose was 2318 g, and mean serum levels of the drug were 947 ng/mL. The mean SLE Disease Activity Index (SLEDAI) was 2.8, and 4.4% had experienced cardiac or retinal toxicity.
On the first study visit, patients gave whole blood samples to have serum hydroxychloroquine levels measured using liquid chromatography in tandem with mass spectrometry or mass spectrometry alone.
Researchers collated data on patient outcomes, including disease activity measured by SLEDAI, and toxicity, notably retinopathy and cardiotoxicity. Analyses were then performed to find the upper threshold for serum hydroxychloroquine levels at which toxicity occurred and the threshold at which a 'ceiling effect' for disease response occurred. Data were also analyzed according to patients' eGFR at the baseline visit, and any subsequent visits if available.
Results showed that serum hydroxychloroquine levels in excess of 1150 ng/mL were associated with 2.2-fold increased risk for systemic toxicity, even after excluding retinopathy. Moreover, serum hydroxychloroquine levels above this limit did not appear to provide any further clinical benefit.
Results also showed that having an eGFR < 60 mL/min/1.73 m2— indicating stage 3 or greater chronic kidney disease — was associated with a 2.5-fold greater likelihood of serum hydroxychloroquine levels in excess of 1150 ng/mL, risking toxicity.
Garg told Medscape Medical News: 'Right now, we don't monitor because we didn't know how to interpret the [serum] levels. This study gave data on this.'
In the long run, the findings could mean that patients with serum hydroxychloroquine levels within the proposed target 'get a green check. But if the levels are too high, you might need to scale down the dose.'
This study received no commercial funding. Garg and Kim had no financial disclosures or conflicts of interest to report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Macron says Europe must become 'space power' again
President Emmanuel Macron said Friday that Europe must again become a global space power, warning that France risked being squeezed out of the global low-orbit satellite constellation market. Macron spoke at the Paris Air Show in Le Bourget outside the French capital a day after France more than doubled its stake in satellite operator Eutelsat, the EU rival to Elon Musk's Starlink. Macron called for more investment as the European space industry struggles to remain competitive in the face of US and Chinese rivals. "SpaceX has disrupted the market, Amazon is also getting involved. China is not far behind, and I think we all need to be very clear-headed," Macron said. Europe must become "a space power once again, with France at its heart", he said. He warned that Europeans were "on the verge of being completely" squeezed out of the low Earth orbit (LEO) satellite constellation market. Orbiting just a few hundred kilometres above the Earth, low Earth orbit satellite networks can play a crucial role in various fields including telecommunications, emergency response, space exploration, and defence. Growing geopolitical tensions have forced countries to focus on the independence of their satellite infrastructure. Macron said France and its partners should not be reliant on non-European constellations in low orbit, calling it "madness". He called non-European players to team up with France. "This must be the solution for our major strategic partners in the Gulf, India, Canada and Brazil," he said. "We really need to succeed in increasing our collective investment effort," Macron added, noting the importance of private investors and public-private collaboration. He also said France planned to organise a space summit in early 2026 to "mobilise our public and private partners across the globe." As part of the overall deal with other investors worth 1.35 billion euros ($1.5 billion), the French state is set to become Eutelsat's largest shareholder. The European satellite operator is vying to be seen as an alternative to Starlink, as companies in Europe and elsewhere look askance at Musk's manoeuvrings and seek to secure sovereign solutions. Boasting more than 600 satellites since merging with British firm OneWeb in 2023, Eutelsat is the world's second-largest operator of low Earth orbit satellites, behind Starlink. fff-tq-as/ekf/js
Bloomberg
5 hours ago
- Bloomberg
UK Heat Wave Could Claim Nearly 600 Lives This Week, Experts Warn
Scientists have warned the elderly and other vulnerable groups in the UK are at risk of heat-related deaths this weekend, as a new study shows recent high temperatures could claim 570 lives in just over four days. Researchers at the London School of Hygiene & Tropical Medicine and Imperial College London published on Saturday a real-time analysis calculating the number of heat-related deaths expected from Thursday to Sunday.
Yahoo
7 hours ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
